4-(乙氧羰基)-3-氟苯硼酸 | 874288-38-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(乙氧羰基)-3-氟苯硼酸
• 中文别名: 4-(乙氧羰基)-3-氟苯基硼酸；4-乙氧基羰基-3-氟苯硼酸
• 英文名称: 4-(ethoxycarbonyl)-3-fluorophenyl boronic acid
• 英文别名: 4-(ethoxycarbonyl)-3-fluorophenylboronic acid；3-fluoro-4-(ethoxycarbonyl)phenylboronic acid；4-Ethoxycarbonyl-3-fluorophenylboronic acid；(4-ethoxycarbonyl-3-fluorophenyl)boronic acid
• CAS: 874288-38-7
• 化学式: C₉H₁₀BFO₄
• mdl: MFCD06656274
• 分子量: 211.985
• InChiKey: CXSPPZZTTSHTMP-UHFFFAOYSA-N

物化性质

• 熔点：
  158-161
• 沸点：
  370.5±52.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.27
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R22,R26,R36/37/38
• 海关编码：
  2931900090
• 安全说明：
  S26,S28,S36/37,S45
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(Ethoxycarbonyl)-3-fluorophenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(Ethoxycarbonyl)-3-fluorophenylboronic acid
Ingredient name:
CAS number: 874288-38-7

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10BFO4
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(乙氧羰基)-3-氟苯硼酸 在 N-甲基吗啉 、 potassium phosphate 、 N-碘代丁二酰亚胺 、 水 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.33h， 生成 4-(6-(3-fluoro-4-(4-methylpiperazine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)benzonitrile
  参考文献：
  名称：

  BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF

  摘要：

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。

  公开号：

  US20140371199A1

文献信息

• PIPERIDINE DERIVATIVES FOR GPR119 AGONIST
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP.

  公开号：US20150166480A1

  公开（公告）日：2015-06-18

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型的哌啶衍生物、它们的立体异构体或药用可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢紊乱，包括糖尿病（尤其是II型）及相关疾病。
• [EN] PIPERIDINE DERIVATIVES FOR GPR119 AGONIST<br/>[FR] DÉRIVÉS DE PIPÉRIDINE AGONISTES DE GPR119
  申请人：CHONG KUN DANG PHARM CORP

  公开号：WO2013187646A1

  公开（公告）日：2013-12-19

  The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

  本发明涉及新型哌啶衍生物，其立体异构体或其药学上可接受的盐；制备该化合物的方法；以及包含该化合物的药物组合物。根据本发明，具有GPR119激动剂作用的新型哌啶衍生物可用于治疗代谢性疾病，包括糖尿病（特别是II型）及相关疾病。
• [EN] BICYCLIC HETEROCYCLIC DERIVATIVES AS MNK1 AND MNK2 MODULATORS AND USES THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES BICYCLIQUES À TITRE DE MODULATEURS DE MNK1 ET MNK2 ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2013147711A1

  公开（公告）日：2013-10-03

  The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the MAP kinase interacting kinases MNK2a, MNK2b, MNK1a, and MNK1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, Alzheimer's disease), as well as methods of treating these diseases.

  本发明涉及某些化合物（例如咪唑吡嗪、咪唑吡啶、咪唑吡嗪和咪唑嘧啶化合物），这些化合物作为MAP激酶相互作用激酶MNK2a、MNK2b、MNK1a和MNK1b的抑制剂。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物制备用于预防和治疗疾病（例如增生性疾病（例如癌症）、炎症性疾病、阿尔茨海默病）的药物的用途，以及治疗这些疾病的方法。
• Solution-Phase Parallel Synthesis of a Multisubstituted Cyclic Imidate Library
  作者：Saurabh Mehta、Jesse P. Waldo、Benjamin Neuenswander、Gerald H. Lushington、Richard C. Larock

  DOI：10.1021/co3001605

  日期：2013.5.13

  a diverse 71-member library of multisubstituted cyclic imidates is described. The key intermediates, 3-iodomethylene-containing cyclic imidates, are readily prepared in good to excellent yields by the palladium/copper-catalyzed cross-coupling of various o-iodobenzamides and terminal alkynes, followed by electrophilic cyclization with I2. These cyclic imidates were further functionalized by palladium-catalyzed

  描述了溶液相平行合成的多取代的环状酰亚胺的71元成员库。关键的中间体，即含3-碘亚甲基的环状酰亚胺，很容易通过钯/铜催化的各种邻碘苯甲酰胺和末端炔的交叉偶联，然后用I 2进行亲电环化，以良好至极好的收率制备。这些环状酰亚胺进一步被钯催化的铃木-宫浦，Sonogashira，羰基酰胺化和Heck化学法使用市售结构单元的子库进行功能化。
• Direct Monofluoromethylthiolation with <i>S</i> -(Fluoromethyl) Benzenesulfonothioate
  作者：Qunchao Zhao、Long Lu、Qilong Shen

  DOI：10.1002/anie.201705633

  日期：2017.9.11

  An electrophilic shelf‐stable monofluoromethylthiolating reagent S‐(fluoromethyl) benezenesulfonothioate (1) was developed. In the presence of a copper catalyst, reagent 1 coupled with a variety of aryl boronic acids to give the corresponding monofluoromethylthiolated arenes in high yields. In addition, addition of reagent 1 to alkyl alkenes in the presence of a silver catalyst gave alkyl monofluoromethylthioethers

  开发了一种亲电性稳定的单氟甲基硫醇化试剂S-（氟甲基）苯磺酸氮磺磺酸盐（1）。在铜催化剂的存在下，试剂1与多种芳基硼酸偶联，以高收率得到相应的单氟甲基硫醇化的芳烃。另外，在银催化剂的存在下将试剂1添加到烷基烯烃中以高收率得到烷基单氟甲基硫醚。